Schizophrenia. Schizophrenia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: In addition to the routine treatment of schizophrenia (which includes one of the three antipsychotic drugs: clozapine, risperidone, olanzapine), Sobhan Company Mema
Sponsors
Zanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Having diagnostic criteria (DSM-5) for patients with schizophrenia and at least two years after diagnosis Age 18 to 50 years Receive a fixed dose of antipsychotic for at least 8 weeks and for 4 weeks before enrollment Continue treatment with at least one antipsychotic drug during the study
Exclusion criteria
Exclusion criteria: Outstanding neurological or organic disease in clinical and laboratory studies Existence of another axis-based diagnosis (DSM-5) Coexistence with mental retardation Drug addiction or abuse (except nicotine and caffeine) Inability to communicate High risk of suicide Receive ECT in the last two weeks History of memantine sensitivity Having kidney disease Pregnancy and lactation Do not use safe contraception in women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attention of schizophrenic patients. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: Strop computer test.;Executive performance. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: London Tower Computer Test.;Processing speed. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: Strop computer test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Negative symptoms. Timepoint: In the three time periods before, 8 and 12 weeks after the start of the intervention. Method of measurement: Negative Symptoms Assessment Scale.;The quality of life. Timepoint: Three time periods before, 8 and 12 weeks after the start of the intervention. Method of measurement: Specific quality of life questionnaire for schizophrenic patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJoz Qanbari Reyhaneh
Zanjan University of Medical Sciences
Outcome results
None listed